Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary

Status Recruiting

Clinical Trial Summary

The optimal treatment of HNCUP remains controversial and lacks evidence from prospective randomized trials. The management of these patients relies primarily on surgery and radiotherapy. The role of radiotherapy in sterilizing putative mucosal sites remains controversial. The main debate concerns the extent of the radiation field. Although pan-mucosal irradiation from the nasopharynx to the hypopharynx and bilateral neck nodes reduces the risk of emergence of a mucosal primary or a nodal relapse, it has been associated with significant toxicity and long-term morbidity (mostly xerostomia and dysphagia). Most single institution retrospective studies have not shown any advantage for more extensive irradiation.Therefore, elective mucosal irradiation may might be appropriate only for these patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02764216
Study type	Interventional
Source	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Contact	Guopei Zhu, M.D.
Email	antica@gmail.com
Status	Recruiting
Phase	Phase 2
Start date	January 2010
Completion date	December 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00003943` - Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer.	Phase 2
Completed	`NCT00004005` - Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin	Phase 2
Recruiting	`NCT02590055` - Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary	Phase 2
Completed	`NCT00002507` - Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer	Phase 3
Recruiting	`NCT03740503` - Genomic Investigation of Unusual Responders
Terminated	`NCT00148135` - Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site	Phase 2
Completed	`NCT00003582` - Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer	Phase 1/Phase 2
Completed	`NCT00014456` - Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT04985357` - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Completed	`NCT00357630` - Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary	Phase 2
Active, not recruiting	`NCT01366144` - Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction	Phase 1
Completed	`NCT00004922` - Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors	Phase 2
Recruiting	`NCT05887492` - Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors	Phase 1/Phase 2
Withdrawn	`NCT00119314` - Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin	Phase 2
Completed	`NCT00047125` - Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor	Phase 3
Completed	`NCT00003657` - High-dose ICE With Amifostine	Phase 2
Recruiting	`NCT05461430` - Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Completed	`NCT00873119` - Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary	Phase 2
Completed	`NCT00388024` - PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy	N/A
Completed	`NCT00066781` - Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary	Phase 2